Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
NCT00061672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67
Last updated 2007-08-15
Summary
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Conditions
- Lymphoma, Non-Hodgkin
- Hodgkin's Lymphoma
Interventions
- DRUG
-
ABT-510 - Thrombospondin-1 Mimetic
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Rod Humerickhouse, MD · Abbott
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-30
Countries
- United States
Study Locations
More Related Trials
-
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
NCT01535989 ·Status: COMPLETED ·Phase: PHASE1
-
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT00058461 ·Status: TERMINATED ·Phase: PHASE2
-
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
NCT00816959 ·Status: UNKNOWN ·Phase: PHASE3
-
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
NCT00829205 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT01118845 ·Status: COMPLETED ·Phase: PHASE2
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
NCT00858117 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
NCT05459571 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
NCT05451810 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
NCT02981745 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00081068 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862 ·Status: RECRUITING ·Phase: PHASE3
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
NCT07058103 ·Status: RECRUITING ·Phase: PHASE2
-
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
NCT00286780 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT00770224 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
NCT05138458 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3
-
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3